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PROBLEMS OF THE BIOLOGICALLY EQUIVALENT DOSE
It has long been known that radiation biology plays an important role and it is 
necessary for radiotherapy treatments. The radiation effects on normal and malignant 
tissues after exposure range from a femtosecond to months and years thereafter 
[1,2]. Therefore, to optimize treatment, it is crucial to explain and understand these 
mechanisms [3-5]. Providing a conceptual basis for radiotherapy and identifying the 
mechanisms and processes that underlie the tumor and normal tissue responses 
to irradiation can help to explain the observed phenomena [6]. Examples include 
understanding hypoxia, reoxygenation, tumor cell repopulation, or the mechanisms of 
repair of DNA damage [3,7,8]. The different biological effects of radiation should be 
divided into several phases: physical (interaction between charged particles and tissue 
atoms), chemical (the period during which the damaged atoms and molecules react 
with other cellular components in rapid chemical reactions), and biological (impact 
of the generated lesions on the biological tissue [4]). The following section describes 
the models most often used in radiotherapy. These are simplistic models that actual 
treatments are based, and that are validated and approved [9-12]. 
REFERENCE MODELS
Numerous models exist to evaluate the biological equivalent dose, but the two 
most common are the nominal standard dose (NSD [13]) and linear quadratic (LQ [9]) 
models. The NSD uses the power law described in equation 1 below (Dtol is the tolerance 
dose of the tissue, NSD is a constant, n and t  , N the number of fractions, and T the 
overall treatment time). However, this model has been often criticized [14]. In short, 
some researchers consider and have even shown that the NSD formula is not a valid 
description for all tumors and normal tissues; instead, they maintain that the model 
incorrectly describes the effects of fraction number and treatment duration.
ABSTRACT
The limits of classical equivalent computation based on time, dose, and fractionation (TDF) and linear quadratic 
models have been known for a long time. Medical physicists and physicians are required to provide fast and 
reliable interpretations regarding the delivered doses or any future prescriptions relating to treatment changes. 
In this letter, we propose an outline related to the different models usable for equivalent and biological doses 
that are likely to be the most appropriate. The used methodology is based on: the linear-quadratic-linear model 
of Astrahan, the repopulation effects of Dale, and the prediction of multi-fractionated treatments of Thames.
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   . .n ttolD NSD N T                    (1)
The LQ model is most frequently used in the radiotherapy units. It allows the 
equivalent dose to be easily evaluated for different fractionations. This concept 
involves the 

ratio, as shown in equation 2 below (D is the total dose for a fraction 
size of d gray).
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Is the dose obtained using a 2Gy fraction dose, which is biologically equivalent 
to the total dose D given with a fraction dose of d gray the values of EQD2 may be added 
in separate parts in the treatment plan. This formula may be adapted to fraction doses 
other than 2Gy.
Limitations of the LQ model
The LQ model is frequently used for modeling the effects of radiotherapy at low 
and medium doses per fraction for which it appears to ϐit clinical data reasonably 
well. The main disadvantage of the LQ approach is that the overall time factor is not 
taken into account, because in radiotherapy it is regarded to be more complex than 
previously supposed [3]. It is indeed very difϐicult to include this parameter in the LQ 
equation. However, a technique may be used to integrate a penalty term in Equation 
2. Thus, for Tstop days off treatment, the dose recovered would be Tstop.Dprol, where 
Dprol is the proliferation factor (in Gy/day; for example, 0.22 for laryngeal edema or 
0.15 for rectosigmoid complications). This methodology is essentially validated for 
discontinuation during treatment. As a general rule, the main limitations of using the LQ 
model are linked to repopulation (LQ doesn’t take into account the dose protraction), bi-
fractionated treatments and high-dose fractions (continuously bending survival curve 
versus linear behavior observed at least in some cell lines). Other more sophisticated 
models, however, take into account these weaknesses. We will later see that the LQ 
model requires further theoretical investigation, especially in terms of the biologically 
effective dose (BED). The next section describes the theoretical methodology that we 
propose to compute the BED.
THE EXISTING MODELS
The BED (introduced by Fowler [9]) is a mathematical concept used to illustrate 
the biological effects observed after irradiation. In addition to being easily computable 
(BED= physical dose x relative efϐiciency), this notion is interesting because two 
irradiations with the same BED generate the same radiobiological effects. For this 
reason, it is easy to compare treatments with different doses, fractionations, and 
overall times.
Target volume models
Let us examine two different treatment cases separately. The ϐirst involves 
treatments with a high-dose fraction (one treatment per day, the fraction size d is 
greater than the dt limit; [15]), which requires a linear quadratic linear (LQL) model. 
The second case relates to other treatments (d < dt), where the LQ model is applicable 
to daily multi-fractionation [16].
a. The d > dt case
When the dose per fraction (d) is greater than the LQL threshold (dt ~ 2 α/β), 
the BED is computed using Equation 3 below (one fraction permitted per day). This 
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template regroups Astrahan’s high-dose model [17] and Dale’s repopulation model 
[18] (n is the number of fraction, ( )x  the Heaviside function, 
a
 the parameter of the 
LQL model and Tpot the potential doubling time in day).
   ln 2. . 1 . ( ). .( )/ .tt t k kpot
dBED n d d d T T T T
a T
   
                            
(3)
The second term used in this equation is useful only when the overall time T is 
greater than the Tk value (kick-off time). If this threshold is not achieved, the tumor 
cells are considered to be non-proliferative (early hypoxia).
b. The d ≤ dt case
When the fraction dose is low, it is recommended to use the standard BED equations 
while considering one or more fractions per day (Equation 4). This methodology follows 
the model of Thames [19], who introduces the repair factor Hm related to the amount 
of unrepaired damage (Equation 5). If the inter-fraction interval is reduced below the 
full repair interval (between 6 hours and 1 day), the overall damage from the whole 
treatment is increased because the repair of damage due to one radiation dose may not 
be complete before the next fraction is given. Hm is LQ model correction taking account 
the poly-fractionation, m the number of fraction per day, ɸ the incomplete repair and μ 
the parameter adjustment necessary to take into account the poly-fractionation in the 
model LQ in hours-1.
     ln 2. . 1 1 . . .( )/ .m k kpot
dBED n d H T T T T
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It is worth noting that in the case of mono-fractionation, the Hm factor is null. These 
equations only relate to the target volume calculation. For the organs at risk, the kick-
off time is not relevant, meaning that it is necessary to use a repopulation-speciϐic 
approach. 
Models for organs at risk 
As in the precedent section on target volumes, this section similarly separates 
high and low doses per fraction. The BED formulae are almost equivalent to the target 
volume model; only the terms relating to the lack of dose by proliferation are modiϐied.
a. The d > dt case
To understand this methodology, it is necessary to consult Van Dyk’s law [20]. The 
kick-off time is no longer considered, with the recovered dose   in Gy / dayln 2( . )rec potD T
 
instead being added. The global model is described in Equation 6 below.
  . . 1 . ./tt t rec
dBED n d d d D T
a

 
          
    
(6)
   
b. The d ≤ dt case
In the case of low doses per fraction, the methodology is similar to the target 
volume model: the mH  parameter (Equation 5) is nonetheless required, which allows 
us to take into account more than one fraction per day. As seen in the Equation 7 below, 
the recovered dose is used as in the previous case.
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  d. . 1 1 . ./m recBED n d H D T 
                         
(7)
Proposztion for computational methods for the equivalent dose
The standard models used for the equivalent dose as based on the LQ approach are 
easily exploitable. The main formulation of the model (Equation 2) can be obtained by 
considering the general formula described in the Equation 8 as follows. 
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This equation may be validated using BED methodology. Considering the BED of 
two treatments to be equal, it appears that a simple relation links the two overall doses 
D
1 
(=n
1 
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1
) and D
2 
(= n
2 
.d
2
). The detail of this procedure is shown in the Equation 9 
below.
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                 (9)
In the case of more sophisticated BED formulations, it is not easy to determine a 
simple formula linking the D
1 
and D
2 
doses, as recovery and repopulation signiϐicantly 
complicate the computational principle. Most of the existing software that uses the 
overall time correction does not calculate the equivalent dose; instead, it only provides 
the BED for the chosen treatments. In clinical use, it is more valuable for the physician 
or physicist to work with the equivalent dose in standard fractionation. In this 
context, the proposed methodology is based on an innovative algorithm, which allows 
a cost function extremum to be determined based on BED modeling. To explain this 
methodology, it is necessary to consider two irradiations (Indices 1 and 2), which are 
deϐined by a fraction number (n), dose per fraction (d), and days of discontinuation 
(ja). The corresponding BED is noted as BED1 (n1,d1,ja1) and BED2 (n2,d2,ja2), while the 
cost function f is deϐined in Equation 10 as follows.
 1 1 1 2 2 2 1 1 1 1 2 2 2 2, , , , ,  ( , , ) ( , , )f n d ja n d ja BED n d ja BED n d ja              (10)
In clinical use, it is desirable to compare a radiotherapy trial with one that is 
performed in a conventional manner (generally with 2 Gy per fraction without 
interruption). This concept of a reference dose simpliϐies the issue, as it is thus possible 
to dispense with the days off treatment and multi-fractionation per day in relation to 
the reference treatment. The following example concerns a tumor case with a dose per 
fraction less than dt (second part of the target volume model), while the cost function, 
f, is given in Equation 11. Concerning the three other cases examined in previous 
sections, a similar relationship is found.
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)
The global treatment duration can be seen to be directly associated with the fraction 
number and days off during radiotherapy. Following Equation 11, the 2Gy-per-fraction 
equivalent dose (EQD
2
) for standard treatment with the characteristics , ,n d ja  is given 
by the algorithm shown in Equation 12.
  0
2 0
argmin ,2, , ,
 
2.
ref
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                 (12)
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All of the results obtained in this section were implemented using a Matlab® 
standalone application known as LQL-equiv.
SYNTHESIS OF THE DOSE EQUIVALENT MODELS 
The LQL_Equiv software was developed in collaboration by the CHD Castelluccio 
radiotherapy unit in Ajaccio and the University of Corsica. It is a free software released 
under the GNU license [21]. The source codes, executable ϐile, help ϐiles, and license 
terms are available at http://cyril-voyant.univ-corse.fr/LQL-Equiv_a34.html. Before 
installing this software, it is advisable to refer to the installation guide and to download 
and execute Matlab Component Runtime (MCR 32 bits, version 7.15 or later). This 
latter step is necessary since the application was programmed using the GUI Matlab® 
software (32 bits, v. 7.12) and deployed with the Matlab Compiler® (v. 4.12), which 
use MCR (a standalone set of shared libraries enabling the execution of Matlab® 
applications on a computer without an installed version of Matlab®). Users of the LQL_
Equiv software are advised to provide us with comments on the software, its libraries 
(biological parameters for each organ or tumor type), or any bugs so as to allow us 
to develop the software. It should be noted that the application requires Microsoft 
Windows® (the resolution and colors are for Vista or later versions). It is important 
to note that all of the parameters used for calculating the equivalence are available on 
the graphical interface. Using Matlab™ and the downloadable source codes, it is easy to 
modify or complete these parameters. It is also possible to contact the software authors 
to assist in developing the software. LQL_Equiv is in direct competition with TDF Plan 
developed by Eye Physics LLC, which proposes a multitude of parameters. However, 
the software is dedicated to the calculation of BED and is not really consistent with the 
reference equivalent dose. Moreover, we aimed to develop ergonomic software with 
minimum of adjustable parameters, which ultimately complicate the interpretation 
of the output. These two approaches are nevertheless complementary; for more 
information about the different models used, refer to the TDF Plan website (http://
www.eyephysics.com/tdf/Index.htm). Table 1 presents a comparison between outputs 
of the standard calculation models described in section II (LQ without proliferation and 
α/β = 10 for oral mucosa and 2 for others) and the LQL-equiv software. The difference 
between the two approaches is substantial. The overall time effect and unusual doses 
per fraction result in completely different outputs. The maximum difference is close 
to 25%; this value is linked to the cell repopulation of prostate cancer. In this case, the 
non-speciϐic methods are certainly not usable. 
CONCLUSION
In this letter, we have exposed the compiling results of various published LQ 
model modiϐications, which have been modiϐied to be better suited for specialized 
radiotherapy techniques such as hypo- or hyperfractionation. The LQ model was 
modiϐied to take into account multi-fractionation, repopulation, high-dose fractions, 
and overall time. Moreover, we propose a software program (LQL_equiv), integrating 
all of these concepts regarding the main organs at risk or target volumes. Finally, this 
worklow permits the obtained results to be compared and validated against other 
“homemade” models, with the purpose of harmonizing practices in interested centers. 
However, it is essential not to consider models as “general biological rules”, parameters 
and outputs uncertainties can be very large; this phenomenon is related to the number 
of regression parameters (parsimony principle) and to the data snooping (e.g. failure 
to adjust existing statistical models when applying them to new datasets).
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